Professor of Medicine and Microbiology/Immunology; Chief, Division of Infectious Disease; Director, HIV/AIDS Clinical and Ryan White Programs; Medical University of South Carolina
Infectious Disease
Dr. John M. Kilby, MD
|
|
Give Review
John M. Kilby, MD practices Infectious Disease. He studied medicine at University of Alabama Medical Center. University of Alabama Medical Center is ranked 37 in research and 17 in primary care medicine He has 1 awards "Fellow (FACP)". John M. Kilby, MD is a published doctor. He has 53 papers published. The most current publication "Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry." John M. Kilby, MD accepts Medicare payments and is registered with Medicare.gov.
Publications
- Plasmacytoid Dendritic Cells Mediate Synergistic Effects of HIV and Lipopolysaccharide on CD27+ IgD- Memory B Cell Apoptosis.
- Human immunodeficiency virus pathogenesis: insights from studies of lymphoid cells and tissues.
- Perspectives on inducing efficient immune control of HIV-1 replication--a new goal for HIV therapeutics?
- Prolonged suppression of human immunodeficiency virus type 1 RNA during dual nucleoside reverse-transcriptase-inhibitor therapy in clinical practice.
- Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults.
- Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report.
- Stability in the HIV vDNA pool in peripheral CD4+ T cells of untreated patients by single tube quantitative PCR.
- Histologic examination of bone marrow core biopsy specimens has limited value in the diagnosis of mycobacterial and fungal infections in patients with the acquired imm...
- Images in clinical medicine. Cytomegalovirus esophageal ulcers.
- Evaluation of distinct blood lymphocyte populations in human immunodeficiency virus type 1-infected subjects in the absence or presence of effective therapy.
- Correlation between circulating stromal cell-derived factor 1 levels and CD4+ cell count in human immunodeficiency virus type 1-infected individuals.
- HIV-1 and HAART: a time to cure, a time to kill.
- Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA.
- Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues.
- Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry.
- The yield of bone marrow biopsy and culture compared with blood culture in the evaluation of HIV-infected patients for mycobacterial and fungal infections.
- Severe hyperglycemia in an HIV clinic: preexisting versus drug-associated diabetes mellitus.
- Effects of tapering doses of oral prednisone on viral load among HIV-infected patients with unexplained weight loss.
- Clinical experience with non-nucleoside reverse transcriptase inhibitors: L-697,661 and nevirapine.
- Is there a role for non-nucleoside reverse transcriptase inhibitors in the treatment of HIV infection?
- Nontuberculous mycobacteria in adult patients with cystic fibrosis.
- Therapeutic potential of blocking HIV entry into cells: focus on membrane fusion inhibitors.
- The effect of ritonavir on saquinavir plasma concentration is independent of ritonavir dosage: combined analysis of pharmacokinetic data from 97 subjects.
- SIVcpz in wild chimpanzees.
- Characterization of functional and phenotypic changes in anti-Gag vaccine-induced T cell responses and their role in protection after HIV-1 infection.
- CD8 T-cell responses in early HIV-1 infection are skewed towards high entropy peptides.
- Safety, tolerability, and plasma pharmacokinetics of high-strength formulations of enfuvirtide (T-20) in treatment-experienced HIV-1-infected patients.
- Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV.
- Novel therapies based on mechanisms of HIV-1 cell entry.
- Antibody neutralization and escape by HIV-1.
- A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy.
- Enfuvirtide.
- The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.
- Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.
- Sex, race, and geographic region influence clinical outcomes following primary HIV-1 infection.
- CD8 T-cell proliferative capacity is compromised in primary HIV-1 infection.
- The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection.
- Switching HIV therapies: competing host and viral factors.
- Modeling sequence evolution in acute HIV-1 infection.
- Gender differences in discontinuation of antiretroviral treatment regimens.
- Retroviruses and other latent viruses: the deadliest of pathogens are not necessarily the best candidates for bioterrorism.
- Therapeutic immunization strategies for HIV infection.
- Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection.
- Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA decline.
- The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus ...
- Functionally competent antigen-specific CD127(hi) memory CD8+ T cells are preserved only in HIV-infected individuals receiving early treatment.
- A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral rep...
- A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
- Delayed access to HIV diagnosis and care: Special concerns for the Southern United States.
- Factors associated with delayed initiation of HIV medical care among infected persons attending a southern HIV/AIDS clinic.
- Cost-effectiveness of enfuvirtide in HIV therapy for treatment-experienced patients in the United States.
- Salmonella infections in the setting of AIDS: a serpentine course.
Schools
University Of North Carolina Chapel Hill School Of Medicine
Duke University
University Of Alabama Hospital
Doctors Specialties
- Infectious Disease Medicine
- Infectious Disease
Accepted Insurances
Awards
- Fellow (FACP)
Education
-
University of Alabama Medical Center -
Duke University Hospital -
University of North Carolina at Chapel Hill School of Medicine
Drug Facts
| NPI NUMBER | 1730117714 | |
| NPPES Provider LastName | KILBY | |
| NPPES Provider FirstName | JOHN | |
| NPPES Provider ZIPCode | 294258908 | |
| NPPES Provider State | SC | |
| Specialty Description | Infectious Disease | |
| Total Claim Count | 663.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1730117714 |
| Last Name Of The Provider | KILBY |
| First Name Of The Provider | JOHN |
| View All |
Similar Doctors
|
|
Dr. Rodney M. Snow, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul A. Goepfert, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. James H. Willig, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. David M. Ennis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael S. Saag, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Thomas A. Moore II, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles G. Cobbs, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Ricardo A. Franco, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Craig J. Hoesley, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Eima Zaidi, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. William I. Lapidus, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nicholas J. Van Wagoner, MD |
|
|
Dr. Anthony P. Cannella, MD |
|
|
Dr. Martin Rodriguez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John M. Cafardi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nathaniel B. Erdmann, MD |
|
|
Dr. Tatiana C. Saavedra, MD
This Doctor is OpenDoctor Recommended.
|